Member of Lyonbiopole
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses.
Strategic application domain: Human Medicine
Application market: Infectious Diseases, Pneumology - Respiratory Diseases
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Vaccine
Created on may 16th, 2017 - 28 employees
Address
70 rue saint Jean de Dieu 69007 Lyon
You must be logged in and a member of Lyonbiopôle to see the contacts.
